Resources

The Advocacy Common Agenda will guide our work at all levels of the Federation to achieve Outcome 1 of the IPPF Strategic Framework 2016–2022, namely to ensure that 100 governments respect, protect and fulfil sexual and reproductive rights and gender equality. In doing so, IPPF will contribute to the International Conference on Population and Development Programme of Action, and to the Sustainable Development Goals. The Advocacy Common Agenda is focused on achieving national political change, placing accountability at the centre. IPPF will influence governments to change or uphold laws and policies to ensure that endorsed international agreements are translated into national action to improve the lives of women and girls. We will build on the Federation’s existing skills and experience as a major provider of SRHR to the most vulnerable and underserved populations, and use our Federation presence in 170 countries to work at four interconnected levels of influence: sub-national, national, regional and international.

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Income for the year for the group increased by US$9.5 million (9%)to US$111.9 million due to a large increase in restricted income from US$30.3 million to US$54.1 million netted off against a decrease in unrestricted income of US$14.3 million.  Total group expenditure increased by US$21.6 million to US$114.6 million which led to a group net operating deficit (combined for unrestricted and restricted funds) for the year of US$2.6 million. Total unrestricted expenditure of US$74.8 million includes grants to member associations and partners (US$42.0 million), group secretariat expenditure (US$28.9 million), and fundraising costs(US$3.3 million). The net operating unrestricted deficit for the year was US$17.0 million (2017 surplus: US$8.8 million). Total restricted expenditure of US$39.8 million includes grants to member associations and partners (US$25.2 million), group secretariat expenditure (US$14.0 million), and fundraising costs (US$0.5 million). There was a restricted surplus of US$14.4 million.

Since the early 1990s, the evidence has been inconclusive as to whether using hormonal contraception increases women’s risk of acquiring HIV, particularly among progestogen-only injectable users. Observational studies indicated that women using progestogen-only injectable contraceptive methods may be at higher risk of acquiring human immunodeficiency virus (HIV).  The ECHO trial finds no link between HIV acquisition and the use of DMPA-IM, progestogen implant, and non-hormonal copper IUD. 

The Universal Declaration of Human Rights states that everyone has the right to a standard of living adequate for the health and well-being of themselves and their family, including medical care and necessary social services. Universal Health Coverage (UHC) means all people obtain the health services they need without suffering financial hardship, and universal access to sexual and reproductive health and rights (SRHR) is an integral part of this. SRHR has often been neglected in discussions on UHC, which fail to recognize that reaching UHC is only possible if the unique health needs of women and girls are met. 

The vulnerabilities of marginalised people, including Lesbian, Gay, Bisexual, Transgender, Intersex and Queer (LGBTIQ+) persons, are often exacerbated in disasters, emergencies and crises.  This is including their access to quality and non-discriminatory sexual and reproductive health (SRH) services and information. SRH is a human right and an essential component of the overall health and protection package in a humanitarian response. Providing comprehensive, high-quality SRH services in humanitarian settings requires a multisectoral and integrated approach to reach the LGBTIQ+ community.  Though the LGBTIQ+ community is often more vulnerable, they also have strong capabilities to cope in the aftermath of disasters, and to leverage social networks in preparedness, relief and recovery phases for themselves and their communities, something that the humanitarian community should leverage based on the principles of ‘do no harm’ and ‘leaving no one behind’.

Millions of workers across the world struggle to access sexual and reproductive health services. Reasons for this can range from a general lack of knowledge of health needs and rights, to insufficient time to find or access services due to working hours. IPPF is working with large employers to address these barriers, devising models that provide information and education to workers on their health and rights, and ensure access to quality sexual and reproductive health services that take into account the needs of the workers and the employers. It is estimated that IPPF reaches over 1 million workers annually through health services delivered via engagement in the workplace.

At A Glance provides a pocket sized summary of the Annual Performance data for easy on demand data to answer all your questions. At A Glance is available also in Arabic, French, Japanese, Korean, Portuguese and Spanish. 

This Annual Performance Report presents progress in implementing the Strategic Framework. In 2018, IPPF delivered 223.2 million sexual and reproductive health services and contributed to 163 policy and legal changes in support of sexual and reproductive health and rights.  Each section of the report presents an overview of the key performance results for our four outcome areas and is supplemented with case studies from countries across IPPF.

The Period QuizAbout half the world’s population menstruates at some point in their lives, but periods are still a big taboo in many places. What do you really know about the flow? Find out in our quiz...How many periods does the average person have in a lifetime?Only girls and women get periodsAt what point during the menstrual cycle is someone most likely to get pregnant?How much blood does the average person lose during a period?What proportion of girls in Ghana sometimes miss school due to their periods?What is the lifetime cost of a period in the UK?How many menstruators in India use unsafe materials (such as ashes and mud) to manage their periods?Good try! ? If you learned something new today, scroll down to share this with friends.Great work! ? If you learned something new today, scroll down to share this with friends.